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Review article
Inflammatory bowel disease (IBD) is a chronic relapsing im­
mune­mediated disease of the intestinal tract. Although its pre­
valence is reportedly lower in Asia than in Western countries, 
the rapid increase in the incidence of IBD has drawn attention 
to its etiology, including genetic susceptibility and environmental 
factors. Specifically, recent studies concerning dietary treatments 
and intestinal microbiota suggest that these factors may interact 
with the immune system, and the imbalance of this relationship 
may lead to immune dysregulation in IBD. Changes in diet or 
alterations in the composition of the intes tinal microbiota may 
be associated with the increasing incidence of IBD in Asia. 
Here, we aim to review recent studies on the role of diet and 
intestinal microbiota in IBD pathogenesis and the results of the 
investigations performed to modulate these factors.
Key words: Inflammatory bowel disease, Diet, Microbiota, 
Fecal microbiota transplantation
Introduction
Inflammatory bowel disease (IBD), including Crohn disease 
(CD) and ulcerative colitis (UC), is an immune­mediated chro­
nic relapsing inflammatory condition that mainly affects the ga­
strointestinal tract.
The incidence and prevalence of IBD is increasing globally. 
Although reportedly higher in Western countries, a similar trend 
is now being observed in Asia as well. The prevalences of CD and 
UC in Canada in 2008 were 255.2 per 100,000 (95% confidence 
interval [CI], 252.4–258.0) and 259.7 per 100,000 (95% CI, 
256.9–262.5), respectively, while the prevalences of CD and 
UC in the commercially­insured in the commercially­insured 
adult population in United States during 2008–2009 were 241.3 
(95% CI, 238.1–244.5) and 263.0 (95% CI, 259.7–266.4) per 
100,000, respectively.1,2) In European studies, prevalences as 
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high as those in North America have been reported.3) Unlike 
in Western countries, epidemiologic data for IBD in Asia are 
relatively lacking, but the prevalence of IBD in these areas is 
thought to be lower. In a Japanese study, the prevalences of CD 
and UC in 2005 were 21.2 (95% CI, 20.8–21.7) and 63.6 (95% 
CI, 62.8–64.4) per 100,000, respectively.4) In South Korea, the 
adjusted prevalences of CD and UC per 100,000 in 2005 were 
11.24 (95% CI, 9.29–13.18) and 30.87 (95% CI, 27.47–34.27), 
respectively.5) However, according to Korean cohort studies, the 
mean annual incidence seems to have increased by more than 
100­fold for both CD and UC in the past 20 years.5)
Increasing occurrences are also being seen in pediatric patients. 
From 1994 to 2009, the incidence of IBD in children increased 
from 9.4 per 100,000 (95% CI, 8.2–10.8) to 13.2 per 100,000 
(95% CI, 11.9–14.6) (P<0.0001).6)
Various factors seem to contribute to the increasing global 
incidence of IBD, including an increased awareness of the 
disease, more developed disease surveillance systems, improved 
accessibility to hospitals and health care providers, and lifestyle 
changes toward a Westernized environment.7) Although genetic 
factors appear to play an important role in the pathogenesis of 
IBD as shown in Swedish cohort studies on identical twins, 
environmental changes over the past few decades have been 
among the important factors increasing the incidence of IBD 
in Asia.3,8,9) This is supported by the higher incidence of illness 
among immigrants who migrate from countries with a low 
incidence to Western countries.10)
The environmental changes and subsequent alterations to the 
intestinal microbiota are considered important in the increased 
prevalence of IBD in Asia. Therapeutic approaches involving 
these factors demonstrating efficacy in recent studies also sup­
port this proposition.11­17) In this review, we will discuss the 
environmental, nutritional, and microbial factors that contribute 
to the pathogenesis of IBD as well as therapeutic approaches to 
modulate these factors.
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Intestinal microbiota and IBD
The human microbiota consists of about 1,014 diverse mi­
crobes, primarily in the colon.33) The gut microbiota affects 
human health by performing many roles in metabolite synthe sis, 
barrier function, and immune responses.34) There is an interaction 
between the gut microbiota and the host immune system; when 
this balanced relationship is disrupted, gut microbial composition 
changes occur that consequently aggravate permeability dysfunc­
tion.35) This, in turn, further aggravates alteration of the microbial 
composition, i.e., dysbiosis, to which a chronic inflammatory 
response occurs in the host immune system.
The intestinal microbiota is also known to have an important 
role in the pathogenesis of IBD.36) Many studies have shown 
lower microbial diversity and a higher microbial dysbiosis index 
in IBD patients compared to healthy controls. Moreover, a long­
term follow­up study of fecal microbiota in patients with IBD 
showed that the microbial profiles of IBD patients are different 
from those of healthy controls, and high volatility was observed 
in IBD patients.37)
Some specific changes in the intestinal microbiota of IBD 
patients have been identified, such as decreases in Roseburia 
hominis and Faecalibacterium prausnitzii, butyrate­producing 
species.38) There are reports of an increased amount of Entero­
bacteriaceae and a reduced number of Clostridium clusters IV 
and XVIa during disease­associated inflammation in newly 
diagnosed CD patients.39) Increases in Escherichia coli, Fusobac­
terium, and Proteus as well as decreases in Firmicutes such as 
Faecalibacterium prausnitzii have also been reported.3)
In newly diagnosed pediatric IBD patients, an increased 
amount of Proteobacteria and a decrease in Faecalibacterium 
prausnitzii in the intestinal microbiota seem to be associated 
with complicated disease phenotypes and a subsequent need for 
biologic therapy or surgery.40)
Diet and microbiota
Colonization of the gut begins at birth, and the gut microbiota 
become more stable and develop adult­like complexity during 
the first year of life.41) Various environmental factors, such as diet, 
are known to contribute to this phenomenon, which begins very 
early in life. A higher proportion of Bifidobacteria was found in 
breastfed than formula­fed infants.42) As previously mentioned, 
dietary patterns are associated with the pathogenesis of IBD and 
are related to the intestinal microbiota. In a mouse model, mice 
fed a high­fat diet demonstrated dysbiosis characterized by an 
increase in Proteobacteria and decrease in Firmicutes, similar to 
that observed in CD.43) A high­fat diet results in the accumulation 
of secondary bile acids, which in turn can inhibit the growth of 
the Bacteroidetes and Firmicutes phyla, a common dysbiotic 
feature found in CD.44)
These varied evidences suggest that the dietary pattern influ­
ences the composition of the intestinal microbiota; through this 
Diet as an environmental factor
Dietary patterns and nutritional factors are considered im­
portant environmental factors in the etiology of IBD, and the 
Western diet has long been suspected of contributing to the 
development of IBD.10) This diet is characterized by high levels 
of fats and refined sugars and low levels of fiber and vegetables. 
Several studies, although many were animal studies, have shown 
that the Western diet is associated with increased levels of pro­
inflammatory cytokines, modulated intestinal permeability, and 
altered composition of the intestinal microbiota that promote 
chronic inflammation in the gut.18­21)
Sakamoto et al.22) found a positive association between sugar 
consumption and CD risk (odds ratio [OR], 2.83; 95% CI, 1.38–
5.83) and UC (OR, 2.86; 95% CI, 1.24–6.57). This supports 
views on the detrimental effects of refined carbohydrates and 
sweetened beverages in the Western diet on IBD. On the con­
trary, complex carbohydrates and fiber­rich vegetables and fruits 
are thought to be beneficial.23) Haskey et al. showed that a high 
protein intake, especially from animal protein, resulted in a 3.3­
time increased risk of IBD, suggesting that a diet high in animal 
protein was a major risk factor.23) With respect to the intake of 
dietary fats, a high n­3 polyunsaturated fatty acid (PUFA) to n­6 
PUFA ratio is reportedly inversely associated with the risk of 
IBD.23­25)
Several studies have shown the influence of certain components 
contained in food on epithelial cell permeability. For ex ample, 
Söderholm et al.26,27) found that sodium caprate, a medium­chain 
fatty acid in dairy products, increased the intestinal per me ability 
in the ilea of rats and humans, more noticeably in those with CD. 
Lammers et al.28) proved that gliadin, the toxic component of 
gluten that initiates the inflammatory response in celiac disease 
binds to C­X­C motif chemokine receptor 3 in the small intestine 
epithelium to increase zonulin release in a myeloid­differentiating 
primary­response 88­dependent manner and subsequently in­
creases intestinal permeability. Increased intestinal perme ability 
is associated with a defective mucosal barrier, which exposes the 
luminal bacteria and their products to the mucosa. An influx of 
the luminal contents to the intestinal mucosa triggers immune cell 
activation and cytokine production and secretion.29)
Aside from the nutritional food components, food additives 
such as detergents and emulsifiers may be associated with de­
fective barrier function.30) Chassaing et al.31) documented in an 
animal study that chronic exposure to carboxymethylcellulose, 
a widely used cellulose derivative used as a viscosity modifier 
in a variety of dairy products, sauces, and sausages, increased 
bacterial adherence to the intestinal epithelium, particularly pro­
inflammatory microbiota. Another food emulsifier common ly 
used in processed food, polysorbate­80, increased the translo­
cation of Escherichia coli across M cells and Peyer’s patches in 
patients with CD.32)
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indirect mechanism, diet can determine subsequent intestinal 
inflammation (Fig. 1).
Environmental modification as treatment
1. Dietary modification
Exclusive enteral nutrition (EEN) is the only evidence­based 
dietary treatment for IBD. EEN involves a completely liquid diet 
without any normal dietary components for a certain duration. It 
is used as a therapeutic method to induce remission in pediatric 
patients with active CD.45)
According to a meta­analysis, EEN is as effective as cortico­
steroids at inducing remission in pediatric CD patients. This 
is true for newly diagnosed CD and relapsed cases (OR, 0.76; 
95% CI, 0.29–1.98). Furthermore, EEN was more effective than 
corticosteroids with respect to mucosal healing (OR, 4.5; 95% 
CI, 1.64–12.32).46) Based on these results, the European Crohn’s 
and Colitis Organization and the European Society for Paediatric 
Gastroenterology Hepatology and Nutrition (ESPGHAN) con­
sensus guidelines on the medical management of pediatric CD 
recommended EEN as the first­line therapy to induce remission 
in children with active luminal CD.47) Although its mechanisms 
are not yet fully understood, there is some evidence that EEN 
reinforces the epithelial barrier; accordingly, bacterial invasion 
into the mucosa is prevented. Moreover, strengthening the 
barrier can restore intestinal microbial dysbiosis and affect the 
dysregulated immune system by decreasing pro­inflammatory 
cytokines as well as the local action of anti­inflammatory cyto­
kines. In this way, EEN is thought to improve inflammation in 
CD.48)
Despite the safety and efficacy of EEN for inducing remission 
in pediatric CD patients, intolerance of or poor adherence to is 
the main hindrance to implementing this therapeutic method.49) 
A recent randomized clinical trial by Levine et al.11) showed that 
the combination of the Crohn disease exclusion diet (CDED) 
and partial enteral nutrition (PEN) induced sustained remission 
at week 12 compared to EEN (75.6% and 45.1%, respectively, 
P=0.01). Moreover, significantly higher tolerance was noted in 
patients who received CDED with PEN than those treated with 
EEN (97.5% and 73.7% respectively, P=0.002).
Table 1 shows various attempts to develop a new dietary 
treatment method for IBD to target the modulation of intestinal 
microbiota or the immune system itself.11,50­60) However, there 
is insufficient evidence to propose a recommendation. A recent 
position paper on behalf of the Porto Inflammatory Bowel 
Disease Group of the ESPGHAN also stated that “elimination 
or restrictive diet in children/adolescents with IBD should not be 
recommended unless potential benefits outweigh potential risks 
of the diet.”61)
2. Use of probiotics and prebiotics in the treatment of IBD
Ever since intestinal microorganisms were known to attribute 
to the pathogenesis of IBD, efforts have been made to restore the 
Fig. 1. Relationship between diet, intestinal microbiota, and inflam­
matory bowel disease (IBD). Genetic susceptibility, diet, and micro bial 
composition contribute to the incidence of inflammatory bowel disease. 
Inflammatory bowel disease itself and its severity are responsible for 
the microbial composition; conversely, dysbiosis is also thought to affect 
inflammatory bowel disease.
Table 1. Summary of the various dietary treatments for IBD other than EEN
Diet Composition and rationales of the diet Literatures
Specific carbohydrate diet Diet originally developed for Celiac disease which excludes complex carbohydrates and 




CD­TREAT diet Individualized and revised version of EEN that mimics the composition of EEN using 
ordinary food
Prospective study
Crohn disease exclusion diet Avoidance of sauces except some specific spices and herbs, gluten, dairy products, gluten 
free baked goods and breads, animal fat, processed meats, food products containing 
emulsifiers, canned goods, and all packaged products which hypotheti cally affect the 





A nutritional regimen as an adjunctive dietary therapy for IBD that restricts the intake of 
certain carbohydrates, but includes pre­ and probiotic food, modified dietary fatty acids 
and food texture
Retrospective case series
IgG4 exclusion diet Diet excluding food with high IgG4 titer RCTs
Low FODMAP diet Avoidance of poorly absorbed short­chain carbohydrates in order to elude bacterial 
fermentation or water shedding into the lumen
Pilot study
RCTs
IBD, inflammatory bowel disease; EEN, exclusive enteral nutrition; CD­TREAT, Crohn's disease treatment­with­eating; IBD­AID, inflammatory bowel disease­
anti inflammatory diet; FODMAP, fermentable oligo­,di­,monosaccharides and polyols;  RCT, randomized controlled trial.
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altered microbial composition. The administration of probiotics 
and prebiotics as IBD treatment has obtained inconsistent results. 
21)
Probiotics are defined as live microorganisms that are bene­
ficial to the host’s health when ingested in adequate amounts. 
Derived from commensal microbiota, they mimic the homeo­
static effect of intestinal microbiota in the healthy condition. 
They affect the mucosal immune system by balancing pro­ and 
anti­inflammatory components, alter the microbial composition 
by inhibiting pathogenic bacteria, and enhance barrier func­
tion.62­65)
Although many probiotics demonstrated limited efficacy in 
UC, the probiotic cocktail VSL#3 and Escherichia coli Nissle 
1917 reduced active inflammation in many studies.66­69) They 
were associated with increased mucosal regulatory T cells, reduc­
ed pro­inflammatory cytokines, increased microbial diversity, 
and restored barrier integrity. However, they showed no statis­
tically significant impact for treating CD.70,71) In addition, several 
microbes such as Faecalibacterium prausnitzii and Bac teroides 
fragilis have been studied for their therapeutic poten tial as they 
seem to reduce colitis severity in many mouse models.72­74)
As shown above, some taxa seem to be associated with the 
disease course of IBD by interacting with the immune system.38­40) 
However, the changes of specific microbiota that increase the 
risk of IBD are not completely clear. Therefore, it is important 
to manipulate specific microbiota and enhance the overall en­
vironment of beneficial microorganisms. Moreover, the fact 
that dietary modification affects the disease course of IBD also 
suggests the significance of prebiotics as a nutrient source for the 
microbiota.
Prebiotics are nondigestible food components fermented by 
microbiota that benefit the host. By providing essential food to 
the microbiota, prebiotics can modify the gut microbial com po­
sition and subsequent metabolites. For instance, oligosaccharides 
and fibers induce the proliferation of short­chain fatty acid­
producing bacteria, such as the Bacteroides genus, to improve 
colitis severity in IBD.75,76) Many in vitro and animal studies 
also confirmed that prebiotics helped alleviate colitis severity by 
altering the microbial composition, production of short­chain 
fatty acids such as butyrate, and balances in pro­ and anti­inflam­
matory cytokines.77­80)
Several human studies have confirmed the efficacy of prebio­
tics in IBD patients, but the results are controversial. Lindsay 
et al. showed a reduced disease activity index and increased 
mucosal Bifidobacteria when CD patients were provided with 
15 g of fructooligosaccharides (FOS).81) However, a randomized 
trial conducted by Benjamin et al.82) showed no significant im­
provement in disease activity in a population that received FOS, 
although it demonstrated an increase in interleukin (IL)­10­
producing dendritic cells (DCs) and decrease in IL­6­producing 
DCs. Other than FOS, germinated barley foodstuff, Ispaghula 
husk, and a combination of oligofructose and inulin demon­
strated the potential to induce remission or reduce in flammation 
in UC patients, while inulin showed its efficacy in pouchitis 
patients as well.83­86)
As describe above, probiotics and prebiotics are thought to play 
distinct roles in immune system regulation. Although they are 
considered feasible armamentaria in the modulation of intestinal 
microbiota and possible treatment options for IBD, many clini­
cal trials on this subject are tremendously heterogeneous in study 
design, mode of administration, and used probiotics or prebio­
tics to lead to a firm conclusion. Therefore, further well­designed 
studies of larger populations are needed to determine which 
probiotics or prebiotics effectively treat IBD.
Intestinal microbiota modification as a treat­
ment using fecal microbiota transplantation
Fecal microbiota transplantation (FMT) is another approach 
to modulating the intestinal microbiota. FMT is considered 
the most direct method to manipulate the intestinal microbiota 
profile, and there is much ongoing research regarding FMT as a 
potential treatment for IBD.
As the first case of FMT in pseudomembranous colitis was 
reported several decades ago, FMT has been well studied and 
proven as an effective and safe treatment for refractory or re­
current Clostridium difficile infection.87) This has stimulated 
research in FMT for other diseases related to dysbiosis, including 
IBD.
Although there are no available randomized controlled trials 
(RCTs) of CD patients, 6 uncontrolled cohort studies were re­
ported with controversial results.12) Vermeire et al.13) reported a 
0% remission rate among patients with moderate to severe CD, 
whereas Cui et al.14) reported a 76.7% clinical remission rate 
after 4 weeks of FMT. Although a meta­analysis of the 6 pooled 
cohort studies showed a clinical remission rate of 52%, RCTs 
with a larger number of patients are needed to ensure the efficacy 
of FMT in CD patients.88)
In contrast to CD, larger RCTs have been performed in UC 
patients. A clinical remission rate of 24%–50% was reported in 
an FMT group; in 3 of 4 studies, remission rates were signifi­
cantly higher in the FMT group than in the control group.15­17,88) 
A meta­analysis of 4 RCTs also showed a significant benefit in 
clinical remission (pooled OR, 2.89; 95% CI, 1.36–6.13; P= 
0.006).88) Subsequently, the American Gastroenterological Asso­
ciation stated the efficacy of FMT for inducing remission in mild 
to moderate UC.89)
In pediatric patients, there are no published RCTs, but 6 cohort 
studies assessing 34 UC patients and 2 cohort studies assessing 13 
CD patients showed a pooled estimated clinical remission rate of 
23% (95% CI, 7%–51%) in UC and 54% (95% CI, 28%–78%) 
in CD patients.88) The clinical trials and their results of FMT in 
pediatric IBD patients are summarized in Table 2.90­100)
When there was a thorough investigation of donor fecal 
material, FMT has been considered a relatively safe treatment 
modality with a low rate of adverse events. Any reported side 
effects were mild and self­limiting.101) Although serious adverse 
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events (SAEs) such as flares were reported in several studies, a 
recent meta­analysis showed no significant difference between 
the FMT and the control groups with respect to SAEs. The 
pooled rate of SAEs was 7.1% in the FMT group versus 5.1% 
in the control group with no significant difference (risk ratio 
adverse events, 1.40; 95% CI, 0.55–3.58; P=0.49).102)
FMT can be considered a relatively safe and effective treat­
ment option for IBD that modulates the intestinal microbiota. 
However, several factors affecting FMT outcome and efficacy 
remain to be determined, including pretreatment, dosage and 
frequency, preparation of donor stools, and routes of admini­
stration. Further studies are needed to increase our understanding 
of and optimize FMT in IBD.12)
Conclusion
Numerous environmental factors can contribute to the in­
creasing incidence of IBD. Of them, dietary and nutritional 
factors play an important role in the pathophysiology directly 
or through changes to the intestinal microbiota. In this “biologic 
era” in which a variety of new potent medications is being used, 
modifying causative environmental factors is still expected to 
play a more fundamental role in treating and preventing IBD. To 
increase our understanding of IBD, it is necessary to focus on the 
medical management and elucidate the environmental factors 
such as dietary treatment and FMT.
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Enema Related and 
unrelated
Fresh 5 Consecutive days Week 1: 3/9
  (33%)
Week 4: 3/9 
  (33%)
Week 1: 7/9 
  (78%)




  et al., 201591)
3 Immunotherapy 
de pendent but 
con trolled 
(Mayo 0–1)
Colonoscopy followed by 
enemas




weekly for 6–12 
weeks)
3/3 (100%) ­ 3 Months
Vandenplas 
  et al., 201592)
1 Severe (PUCAI 
60–75)
Colonoscopy first 2 infusions
Nasoduodenal tube next 5 
infusions
Related Fresh 7 times (interval not 
shown)
1 ­ 6 Months




Nasogastrtuc tube NR Fresh Single 0 0 12 Weeks
Shimizu et al., 
201696)
1 Severe, steroid 
dependent UC
Colonoscopy first 1 infusion
Enema next 4 infusions (5–
day course), then 11 
infusions for 10 months/
Related Fresh 16 Times for 10 
months
1 0 10 Months
Pai et al., 
201695)





1 Severe (PUCAI 
85)
Enema first 2 infusions, 
Nasoduodenal tube next 
4 infusions












Unrelated NR 5 Consecutive days
3 Days alternatively
3/8 (37.5%) 7/8 (87.5%) 4 Weeks




Both gastroscopy (20–30 




Fresh Single 6 Months: 
  0/14 (0%)
1 Month: 7/14
   (50 %)
6 Months: 3/14 
(21.4 %)
6 Months
Yodoshi et al., 
201899)
2 Severe refractory 
UC
Colonoscopy for one pati­
ent, and Nasoduodenal 
tube for another (As de­
sired)
Related Fresh 5 Consecutive days Week 3: 2/2
Week 4: 1/2





















Unrelated NR 5 Consecutive days
3 Days alternatively
2/2 (100%) 2/2 (100%) 4 Weeks




Both gastroscopy (20–30 




Fresh Single 6 Months: 2/7 
(28.6 %)
1 Month: 5/7 
(71%)
6 Months: 3/7 
  (43 %)
6 Months
IBD, inflammatory bowel disease; UC, ulcerative colitis; CD, Crohn disease; PUCAI, pediatric ulcerative colitis activity index; NR, not reported. 
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reported. 
See the commentary "Dietary role in the development and 
treatment of inflammatory bowel disease" via https://doi.
org/10.3345/cep.2020.00080.
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